BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 18315876)

  • 1. Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors.
    Cook D; Douketis J; Meade M; Guyatt G; Zytaruk N; Granton J; Skrobik Y; Albert M; Fowler R; Hebert P; Pagliarello G; Friedrich J; Freitag A; Karachi T; Rabbat C; Heels-Ansdell D; Geerts W; Crowther M;
    Crit Care; 2008; 12(2):R32. PubMed ID: 18315876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dalteparin versus unfractionated heparin in critically ill patients.
    ; Cook D; Meade M; Guyatt G; Walter S; Heels-Ansdell D; Warkentin TE; Zytaruk N; Crowther M; Geerts W; Cooper DJ; Vallance S; Qushmaq I; Rocha M; Berwanger O; Vlahakis NE
    N Engl J Med; 2011 Apr; 364(14):1305-14. PubMed ID: 21417952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency.
    Rabbat CG; Cook DJ; Crowther MA; McDonald E; Clarke F; Meade MO; Lee KA; Cook RJ
    J Crit Care; 2005 Dec; 20(4):357-63. PubMed ID: 16310608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.
    Douketis J; Cook D; Meade M; Guyatt G; Geerts W; Skrobik Y; Albert M; Granton J; Hébert P; Pagliarello G; Marshall J; Fowler R; Freitag A; Rabbat C; Anderson D; Zytaruk N; Heels-Ansdell D; Crowther M;
    Arch Intern Med; 2008 Sep; 168(16):1805-12. PubMed ID: 18779469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonleg venous thrombosis in critically ill adults: a nested prospective cohort study.
    Lamontagne F; McIntyre L; Dodek P; Heels-Ansdell D; Meade M; Pemberton J; Skrobik Y; Seppelt I; Vlahakis NE; Muscedere J; Reece G; Ostermann M; Padayachee S; Alhashemi J; Walsh M; Lewis B; Schiff D; Moody A; Zytaruk N; Leblanc M; Cook DJ; ; ;
    JAMA Intern Med; 2014 May; 174(5):689-96. PubMed ID: 24638843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors.
    Cook D; Crowther M; Meade M; Rabbat C; Griffith L; Schiff D; Geerts W; Guyatt G
    Crit Care Med; 2005 Jul; 33(7):1565-71. PubMed ID: 16003063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-molecular-weight heparin venous thromboprophylaxis in critically ill patients with renal dysfunction: A subgroup analysis of the PROTECT trial.
    Pai M; Adhikari NKJ; Ostermann M; Heels-Ansdell D; Douketis JD; Skrobik Y; Qushmaq I; Meade M; Guyatt G; Geerts W; Walsh MW; Crowther MA; Friedrich JO; Burry L; Bellomo R; Brandão da Silva N; Costa Filho R; Cox MJ; Alves Silva S; Cook DJ;
    PLoS One; 2018; 13(6):e0198285. PubMed ID: 29856817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
    Leizorovicz A; Cohen AT; Turpie AG; Olsson CG; Vaitkus PT; Goldhaber SZ;
    Circulation; 2004 Aug; 110(7):874-9. PubMed ID: 15289368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis.
    Lauzier F; Arnold DM; Rabbat C; Heels-Ansdell D; Zarychanski R; Dodek P; Ashley BJ; Albert M; Khwaja K; Ostermann M; Skrobik Y; Fowler R; McIntyre L; Nates JL; Karachi T; Lopes RD; Zytaruk N; Finfer S; Crowther M; Cook D
    Intensive Care Med; 2013 Dec; 39(12):2135-43. PubMed ID: 23942857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M;
    N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
    Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
    Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Burden of illness in venous thromboembolism in critical care: a multicenter observational study.
    Patel R; Cook DJ; Meade MO; Griffith LE; Mehta G; Rocker GM; Marshall JC; Hodder R; Martin CM; Heyland DK; Peters S; Muscedere J; Soth M; Campbell N; Guyatt GH; ;
    J Crit Care; 2005 Dec; 20(4):341-7. PubMed ID: 16310605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
    Agnelli G; Becattini C; Meyer G; Muñoz A; Huisman MV; Connors JM; Cohen A; Bauersachs R; Brenner B; Torbicki A; Sueiro MR; Lambert C; Gussoni G; Campanini M; Fontanella A; Vescovo G; Verso M;
    N Engl J Med; 2020 Apr; 382(17):1599-1607. PubMed ID: 32223112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients.
    Jonmarker S; Hollenberg J; Dahlberg M; Stackelberg O; Litorell J; Everhov ÅH; Järnbert-Pettersson H; Söderberg M; Grip J; Schandl A; Günther M; Cronhjort M
    Crit Care; 2020 Nov; 24(1):653. PubMed ID: 33225952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and Predictors of Deep Vein Thrombosis in Critically Ill Medical Patients Who Underwent Diagnostic Duplex Ultrasonography.
    Gibson CD; Colvin MO; Park MJ; Lai Q; Lin J; Negassa A; Shah CD; Langston MD
    J Intensive Care Med; 2020 Oct; 35(10):1062-1066. PubMed ID: 30453801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study.
    Tincani E; Mannucci C; Casolari B; Turrini F; Crowther MA; Prisco D; Cenci AM; Bondi M
    Haematologica; 2006 Jul; 91(7):976-9. PubMed ID: 16757417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients.
    Li G; Cook DJ; Levine MAH; Guyatt G; Crowther M; Heels-Ansdell D; Holbrook A; Lamontagne F; Walter SD; Ferguson ND; Finfer S; Arabi YM; Bellomo R; Cooper DJ; Thabane L;
    Medicine (Baltimore); 2015 Sep; 94(36):e1479. PubMed ID: 26356708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex differences in thromboprophylaxis of the critically ill: a secondary analysis of a randomized trial.
    Burns KEA; Heels-Ansdell D; Thabane L; Kahn SR; Lauzier F; Mehta S; Ostermann M; Bhuptani P; Crowther MA; Finfer S; Cook DJ;
    Can J Anaesth; 2023 Jun; 70(6):1008-1018. PubMed ID: 37310606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should patients with deep vein thrombosis alone be treated as those with concomitant asymptomatic pulmonary embolism? A prospective study.
    Monreal M; Büller H; Lensing AW; Bonet M; Roncales J; Muchart J; Fraile M
    Thromb Haemost; 2002 Dec; 88(6):938-42. PubMed ID: 12529742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deep Vein Thrombosis in Intensive Care.
    Boddi M; Peris A
    Adv Exp Med Biol; 2017; 906():167-181. PubMed ID: 27628009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.